PSYC Revamps Their Online Presence with a Relaunch of Corporate Website

— Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) is pleased to announce that the Company has completed the redevelopment and relaunch of its corporate website; www.globaltracsolutions.com with the intent of showcasing PSYC’s emergence as a digital media leader within the expanding medicinal psychedelic industry. Earlier this year, the Company began the process ofContinue reading “PSYC Revamps Their Online Presence with a Relaunch of Corporate Website”

Revive Therapeutics Announces IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

— Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the Company’s Phase 3 clinical trial protocol to evaluate the safety and efficacy of Bucillamine in patients with mild-moderateContinue reading “Revive Therapeutics Announces IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19”

FDA Approves New Indication for Drug Containing an Active Ingredient Derived from Cannabis to Treat Seizures in Rare Genetic Disease

— Today, the U.S. Food and Drug Administration approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older. Epidiolex was previously approved for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome (LGS) andContinue reading “FDA Approves New Indication for Drug Containing an Active Ingredient Derived from Cannabis to Treat Seizures in Rare Genetic Disease”

Tetra Bio-Pharma Receives Conditional Approval to Graduate to the TSX

Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSXV:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce it has received conditional approval from the Toronto Stock Exchange (the “TSX”) to graduate from the TSX Venture Exchange (“TSX-V”) and list its common shares (“Shares”) and its warrants (“Warrants”) on the TSX, subjectContinue reading “Tetra Bio-Pharma Receives Conditional Approval to Graduate to the TSX”

Infinite CBD Joins Charlotte’s Web in FDA-focused Study on CBD Safety

Infinite CBD Joins Industry Leaders in a Clinical Trial to Provide Evidence of Safety in Cannabinoid Product Use  – Infinite CBD, creators of the original CBD-infused asteroid gummy, announced they will join Charlotte’s Web and other industry-leading CBD businesses as a co-sponsor and participant in ValidCare’s large-scale research study to provide the US Food andContinue reading “Infinite CBD Joins Charlotte’s Web in FDA-focused Study on CBD Safety”

Amended: Naturally Splendid Closes Private Placement

“Prior to COVID-19, the plant-based food category was growing at a rate outpacing traditional food channels and we expect this trend to continue post-pandemic times.” Naturally Splendid Enterprises Ltd. (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) is pleased to announce that it has closed its non-brokered private placement financing for a total of 42,857,159 units (the “Units”) at $0.035Continue reading “Amended: Naturally Splendid Closes Private Placement”

Charlotte’s Web Steps up to Support Research to Address FDA’s Request for More Scientific Data

ValidCare to Conduct Industry Leading Study on CBD and Human Health BOULDER, Colo., June 9, 2020 /PRNewswire/ – (TSX: CWEB) (OTCQX: CWBHF) Charlotte’s Web Holdings, Inc. (“Charlotte’s Web” or the “Company”), the company behind the world’s most trusted hemp extract™ and the CBD industry market leader, announced its sponsorship, with six other CBD brands, of ValidCare’s scientific study, toContinue reading “Charlotte’s Web Steps up to Support Research to Address FDA’s Request for More Scientific Data”

Naturally Splendid Closes Private Placement

“Prior to COVID-19, the plant-based food category was growing at a rate outpacing traditional food channels and we expect this trend to continue post pandemic times.“ Naturally Splendid Enterprises Ltd. (“Naturally Splendid”) (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) is pleased to announce that it has closed its non-brokered private placement financing for a total of 42,857,159 units (the “Units”)Continue reading “Naturally Splendid Closes Private Placement”

FSD Pharma Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis

TORONTO, June 3, 2020 /CNW/ – FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has given the company permission to submit an Investigational New Drug Application (IND) for the use of FSD-201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA)  to treat COVID-19, the disease caused by the SARS-CoV-2 virus.Continue reading “FSD Pharma Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis”